Back to top
more

Bristol Myers Squibb (BMY)

(Real Time Quote from BATS)

$44.15 USD

44.15
1,295,772

-0.49 (-1.10%)

Updated Apr 30, 2024 10:10 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (79 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..

Sweta Killa headshot

Trump Attacks Biotech & Pharma: ETFs Bleed

by Sweta Killa

Trump pledged to initiate a bidding process for drug cost that shed roughly $24.6 billion in 20 minutes from the nine biggest pharmaceutical companies by market cap.

    Roche Gets Priority Review for Immunotherapy Drug Tecentriq

    by Zacks Equity Research

    Roche Holding AG's (RHHBY) Genentech announced that the FDA has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for cancer immunotherapy, Tecentriq.

      Bristol-Myers, GeneCentric Tie Up for Opdivo Biomarker Study

      by Zacks Equity Research

      Bristol-Myers (BMY) and GeneCentric Diagnostics inked an exploratory biomarker research collaboration.

        Bristol-Myers, J&J Ink Immunotherapy Research Collaboration

        by Zacks Equity Research

        Bristol-Myers (BMY) entered into an immunotherapy clinical research collaboration with Johnson & Johnson to evaluate a combination of Opdivo and Darzalex.

          Arpita Dutt headshot

          Pharma Stock Roundup: PCSK9 Inhibitor Praluent in News, Allergan's Preliminary 2017 View

          by Arpita Dutt

          Key highlights this week include a court injunction blocking sales of PCSK9 inhibitor Praluent and preliminary guidance from Allergan (AGN).

            Bristol-Myers Extends Deal with Five Prime Therapeutics

            by Zacks Equity Research

            Bristol-Myers (BMY) has exercised its option to extend the research term of the existing collaboration agreement with Five Prime Therapeutics (FPRX).

              4 Reasons Why Pfizer (PFE) Could be a Great Pick in 2017

              by Zacks Equity Research

              Pfizer's shares surpassed that of large-cap pharma industry in 2016. The stock rose 0.6% in 2016.

                ARIAD Stock Beats Industry in 2016, Iclusig Sales Strong

                by Zacks Equity Research

                Shares of ARIAD Pharma surged 98.4% year to date and outperformed the Zacks classified Medical-Drugs industry that declined 25.4%.

                  AbbVie's Humira and Imbruvica Drive Performance in 2016

                  by Zacks Equity Research

                  AbbVie Inc.'s (ABBV) share price is up 5.9% so far this year.

                    Arpita Dutt headshot

                    Pharma Stock Roundup: Cempra Plunges to 52-Week Low, Shire Drug Label Expanded

                    by Arpita Dutt

                    Key highlights this week include complete response letters from the FDA for a couple of companies with Cempra (CEMP) plunging to a 52-week low.

                      Portola Betrixaban Accepted for Review in U.S. & EU, Stock Up

                      by Zacks Equity Research

                      Shares of Portola (PTLA) surged 33.8% after the FDA granted priority review to anticoagulant, betrixaban. Betrixaban was also accepted by the EMA for review.

                        Arpita Dutt headshot

                        Pharma Stock Roundup: J&J Back in Talks with Actelion, Teva Settles Corruption Probe

                        by Arpita Dutt

                        J&J (JNJ) and Actelion are back in the limelight with the companies in exclusive talks regarding a possible deal.

                          Bristol-Myers, Calithera Team Up for Opdivo/CB-839 Combo

                          by Zacks Equity Research

                          Bristol-Myers Squibb Company (BMY) announced a clinical trial collaboration with Calithera Biosciences, Inc. (CALA).

                            Bristol-Myers, PsiOxus Ink Deal for Oncolytic Virus Therapy

                            by Zacks Equity Research

                            Bristol-Myers (BMY) inks a deal with PsiOxus for an early-stage oncolytic virus candidate, NG-348.

                              The Zacks Analyst Blog Highlights: Bristol-Myers, Shell, Facebook, Baker Hughes, Eli Lilly and Fifth Third Bancorp

                              by Zacks Equity Research

                              The Zacks Analyst Blog Highlights: Bristol-Myers, Shell, Facebook, Baker Hughes, Eli Lilly and Fifth Third Bancorp

                                Arpita Dutt headshot

                                Pharma Stock Roundup: Drug Pricing Heat Back on Sector, Endo, Mylan, AZN to Cut Jobs

                                by Arpita Dutt

                                Drug pricing is back in focus with president-elect Trump making it clear that he does not like price increases.

                                  Bristol-Myers Reports Data from Opdivo Combination Studies

                                  by Zacks Equity Research

                                  Bristol-Myers (BMY) presented multiple data from Opdivo combination studies.

                                    Arpita Dutt headshot

                                    Pharma Stock Roundup: Nivalis Falls on Study Data, Priority Reviews for Merck's Keytruda

                                    by Arpita Dutt

                                    This week, companies like Merck (MRK) and Pfizer (PFE) provided updates on their pipelines.

                                      Heat Biologics Stock Falls on Negative Bladder Cancer Data

                                      by Zacks Equity Research

                                      Heat Biologics (HTBX) presented disappointing top-line phase II data from the bladder cancer study on its lead pipeline candidate, HS-410.

                                        ARIAD's Leukemia Drug Iclusig Gets Full Approval in U.S.

                                        by Zacks Equity Research

                                        ARIAD Pharmaceuticals, Inc. (ARIA) announced that the FDA has granted a full approval to its leukemia drug, Iclusig (ponatinib), following its successful completion of the commitments made on accelerated approval in Dec 2012.

                                          The Zacks Analyst Blog Highlights: Bristol-Myers, Google, Deere, Halliburton and American Airlines

                                          by Zacks Equity Research

                                          The Zacks Analyst Blog Highlights: Bristol-Myers, Google, Deere, Halliburton and American Airlines

                                            Zacks Industry Outlook Highlights: Bristol-Myers, Biogen, Merck, Celgene and ARIAD Pharmaceuticals

                                            by Zacks Equity Research

                                            Zacks Industry Outlook Highlights: Bristol-Myers, Biogen, Merck, Celgene and ARIAD Pharmaceuticals

                                              Stock Market News for August 10, 2016

                                              by Zacks Equity Research

                                              Benchmarks closed narrowly in the green as drop in oil prices and disappointing productivity data offset some of the gains in healthcare and consumer staples stocks

                                                Stock Market News for August 09, 2016

                                                by Zacks Equity Research

                                                Despite strong crude rally, major benchmarks closed in the red on Monday on the back of declines in healthcare stocks

                                                  Mark Vickery headshot

                                                  BLS Reports Robust July Jobs: 255K, 4.9% Unemployment

                                                  by Mark Vickery

                                                  Also, May's paltry 11K jobs was more than doubled to 24K, and even June's strong 287K rose another 5000 jobs to 292K.